News

Data Reported Comparable Multiple Pregnancy Rates Among Patients Treated with Investigational Milprosa™ and Progesterone Vaginal Gel JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today presented data from a sub-analysis of a Phase III clinical trial of Milprosa™ (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization (IVF). The results were presented at the 61st Annual Meeting of the Pacific Coast Rep Read More »

CONCERTO Study Enrolling Patients Globally to Evaluate Impact of Laquinimod on Disability Progression JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Mar. 6, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today enrollment of the first patient in the CONCERTO study - the third Phase III placebo-controlled study designed to evaluate the efficacy, safety and tolerability of once-daily oral laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS). The Read More »

Data Demonstrated Once-Weekly Milprosa™ Provides Similar Pregnancy Rates to Daily 8 Percent Progesterone Vaginal Gel JERUSALEM--(BUSINESS WIRE)--Mar. 4, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the publication of results of the Phase III clinical trial of Milprosa™ (progesterone) vaginal ring in Fertility and Sterility. The study compared the efficacy and safety of once-weekly Milprosa™ to daily 8 percent progesterone vaginal gel for luteal phase support in in vitro fertilization (IVF) and found Read More »

-Following first, positive trial, second trial fails to demonstrate efficacy in meeting primary and secondary endpoints -Teva remains committed to clinical development program with third, ongoing phase III and open-label extension trials JERUSALEM--(BUSINESS WIRE)--Jan. 23, 2013-- Teva Pharmaceutical Industries Ltd. today announced top-line results of its Phase III clinical program for armodafinil (NUVIGIL®) as adjunct therapy in adults with major depression associated with bipolar 1 disorder. While study 3072 demonstr Read More »

JERUSALEM, Oct 14, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that more than 30 scientific presentations on the company's multiple sclerosis (MS) portfolio, including the market-leading treatment Copaxone(R) and the late-stage oral therapy laquinimod, will be featured during the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS AND ACTRIMS). This year's meeting, recognized as the world's largest annual international conference focused on MS research, will be held in Amst Read More »

Doubled Dose of COPAXONE® Maintained Proven Safety Profile and Further Reduced Relapses and Lesions Jerusalem, Israel, April 17, 2007 - A 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40 mg dose of COPAXONE® given daily to the currentlyapproved COPAXONE® 20 mg dose showed a 38 percent greater reduction in inflammatory disease activity as measured by magnetic resonance images (MRI) of the brain. In addition, patients taking COPAXONE® 40 mg experienced a reduced mean on-trial relapserate of 77 percent when compared to annual relapse rate prior to en Read More »

Jerusalem, Israel and Lund, Sweden, May 1, 2007 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, doubleblind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated. In addition, there was a favorable trend towards reducing annual relapse rates, the number of relapse-free patients and time to first relapse compared with placebo. Treatment with a 0.3 mg dose showe Read More »

Jerusalem, Israel and Lund, Sweden, June 7, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) today announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis (RMS). The studies will now begin following the successful conclusion of a second phase II study and the outcome of discussions with the U.S. Food And Drug Administration (FDA) and the European Medicines Agency (EMEA). The companies are to commen Read More »

Jerusalem, Israel, September 19, 2007 - Jerusalem, Israel, September 19, 2007 Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the Company's synthetic peptide, edratide (TV-4710), did not meet its primary endpoint in the PRELUDE trial, a Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE). The drug candidate, administered as a subcutaneous weekly injection, was shown to be safe and well-tolerated. PRELUDE, a randomized, double-blind, placebo-controlled, parallel assignment Phase 2 study, enrolled 340 patients from 12 countries across North America, Read More »

Jerusalem, Israel, October 12, 2007 - from a 16-year follow-up study of 174 relapsing remitting multiple sclerosis (RRMS) patients was presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The study demonstrates significant clinical benefits on both disability and relapse rates in patients continuously treated with COPAXONE® (glatiramer acetate injection) for an average of 8 years. The majority of patients (84.8 percent) in the ongoing cohort (n=112), who continuously received COPAXONE® showed either unchanged or improved disabilit Read More »